Nashik-based Datar Cancer Genetics claimed that the central regulator had arbitrarily rejected its application to conduct ...

Austin Clinical Trial Partners is one of approximately 70 research sites across the United States participating in a Phase 2 ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported ...

SAN FRANCISCO, May 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

The JADE study will be evaluating BI 1584862, an investigational oral compound that targets inflammation and preserves ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second ...

Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET. Company Participants. Stephanie Fagan - Chief Corporate Affairs Officer Rob Bar ...

We look forward to supporting innovation in the life science industry by continuing to deliver effective risk transfer ...

Two new RCTs of rituximab will soon begin in the United Kingdom: A biomarker-based trial with add-on belimumab and another in ...

Ingelheim, Germany Thursday, May 8, 2025, 14:00 Hrs [IST] ...